INTRODUCTION
Genomic studies have catalogued chromosomal lesions and somatic mutations in T cell acute lymphoblastic leukemia (T-ALL) (1) (2) (3) . Increased expression of microRNAs (miRNAs) represents an additional mechanism of oncogenesis, and several highly abundant miRNAs promote leukemogenesis through the dominant repression of critical tumor suppressor genes. Of these, the miR-17~92 cluster may be the best-characterized example. Expression of this cluster is occasionally enhanced in Burkitt's lymphoma, and it promotes lymphoma and T-ALL development in experimental models (4) (5) (6) . The oncogenic action of miRNAs is further increased by overlapping and cooperative effects on target genes. In T-ALL, for example, five oncogenic miRNAs (miR-19b, miR-20a, miR-26a, miR-92, and miR-223) converge on a small set of tumor suppressor genes (for example, Pten and Fbxw7) and markedly reduce their expression (7) . Hence, increases in the abundances of individual miRNAs have substantial effects on gene expression and cause various phenotypes, including malignant transformation.
On the other hand, the effects of miRNAs on target genes are highly redundant, an effect that attenuates the consequences of losing individual miRNAs. For example, the average human transcript harbors 70 to 100 3′ untranslated region (UTR)-binding sites, typically representing 16 different miRNAs (8, 9) . Concordantly, comprehensive miRNA knockout studies in Caenorhabditis elegans or in mice often show minor or no apparent phenotypes (10) (11) (12) . Similarly, only a few miRNAs act as tumor suppressors in loss-of-function studies. The best-characterized tumor-suppressive miRNAs are miR-15 and miR-16, which are lost in chronic lymphocytic leukemia (CLL) (13, 14) , as well as miR-146, whose inactivation in mice stimulates a similar proliferation of myeloid cells (15) . Here, we performed a comprehensive analysis of tumor suppressor miRNAs in cancer, and through a computational strategy, we identified a convergence of five miRNAs on MYB and HBP1 oncogenes in T-ALL.
RESULTS

Identification of tumor suppressor miRNAs in T-ALL
We took a systematic and stepwise approach to identify candidate tumor suppressor miRNAs and their unique targets (Fig. 1A) . First, we catalogued all miRNAs that were differentially decreased in abundance in T-ALL patient specimens compared to normal T cells and their precursors. We then tested these miRNAs in gain-and loss-of-function studies and developed a machine learning strategy to identify nonredundant miRNA targets.
First, we compared the amounts of miRNAs in 50 T-ALL samples to those in different normal T cell and precursor populations. We used quantitative reverse transcription polymerase chain reaction + and CD4 + or CD8 + cells) and compared them to those in 50 T-ALL specimens, which included all major cytogenetic subgroups, including MLL (n = 4 patients), CALM-AF10 (n = 3), inversion (7) (n = 5), LMO2 (n = 7), SIL-TAL (n = 8), TLX3 (n = 10), TLX1 (n = 5), and unknown (n = 8), as well as in 18 T-ALL cell lines (table S1) (16) . Overall, the major cytogenetic groups showed broadly similar miRNA abundances (7) . To identify miRNAs that were decreased in abundance in T-ALL cells compared to in normal cells, we used the following thresholds Fig. 2A ). An increase in GFP + cells indicates that the coexpressed miRNAs provided a proliferative advantage to the transduced cells and vice versa. As expected, all 12 miRNAs were detected, albeit at low abundance, in all of the cell lines (table S1) . Of the 12 miRNAs tested, the enforced expression of only miR-29, miR-31, miR-150, miR-155, and miR-200 produced the most consistent antiproliferative effects. Our criteria for defining tumor-suppressive miRNAs were reproducibility and statistical significance (P < 0.05) in triplicate experiments, as well as an antiproliferative effect in three of the four cell lines tested (Fig. 2B) . These criteria were designed to be exclusive in preparation for subsequent loss-of-function studies in vivo; however, miRNAs that did not meet these criteria might still have relevant functions under other specific circumstances ( fig. S2) .
We then performed miRNA loss-offunction studies in a murine T-ALL model.
We used a mouse model based on the adoptive transfer of hematopoietic progenitor cells (HPCs) expressing the intracellular domain of Notch1 (ICN) into irradiated syngeneic mice (Fig. 3A) (17, 18) . ICN is a dominant oncogene product, and it induced T-ALL in 100% of mice with a median latency of 2 months (median survival = 59 days; n = 6 mice); however, we still detected a statistically significant increase in the rate We used miRNA sponges to confirm these effects and to test additional candidate miRNAs for which knockout animals were not available (19) . Briefly, the sponges encode four miRNA seed-specific binding elements, and they efficiently repressed the on-target activities of their cognate miRNAs in reporter assays (fig. S3, A and B). Cotransduction of wild-type HPCs with ICN and the sponges against miR-29 (median survival, 44 days), miR-31 (median survival, 49 days), miR-155 (median survival, 42 days), and miR-200 (median survival, 43 days) accelerated the onset of T-ALL in recipient mice compared to that in mice that received control vectors (median survival, 76 days) (Fig. 3C) . Similarly, sponge-mediated inhibition of these miRNAs in MOHITO cells, a murine T cell line, increased their proliferation compared to that of cells that received a nontargeting sponge ( fig. S3C) .
A third approach to target miRNAs is based on lentiviral miRZips, which act as RNA interference constructs that target specific miRNAs (20) . We found that coexpression of ICN and miRZips specific for miR29a (median survival, 48 days), miR-150 (survival, 60 days), miR-155 (median survival, 62 days), or miR-200 (median survival, 47 days) accelerated leukemia development and confirmed the observations from the experiments with knockout cells and sponges ( fig. S3D ). To exclude any nonspecific effect by the miR-150 miRZip, we introduced the construct into cells from miR-150 −/− mice, but it had no additional effect on leukemia development in recipient mice compared to that in mice that received HPCs from miR-150 −/− mice without miRZip ( fig. S3E ). Pathologically, all ICN-driven leukemias were indistinguishable from each other, because they were THY-1 + and CD4 and CD8 double-positive and they showed minimal infiltration of B cells; aggressive invasion into solid organs; a high proliferative index, as determined by Ki-67 staining; and the absence of apoptosis, as determined by terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) staining ( Fig. 3D and fig. S3 , F and G). Hence, we identified miR-29, miR-31, miR-150, miR-155, and miR-200 as tumor suppressor miRNAs whose abundance was decreased in T-ALL and whose loss promoted leukemogenesis in vivo.
A strategy to identify nonredundant miRNA targets in loss-of-function studies
The large number of genes targeted by miRNAs sometimes obscures the biologically relevant miRNA targets. However, we reasoned that in a loss-of-function setting, this pleiotropy should facilitate target identification. Briefly, among all of the predicted target genes of a given miRNA, only a small number will be affected by loss of that miRNA, whereas the expression of most predicted gene targets will not change and they will be controlled by other miRNAs (Fig. 4A ). In practice, we computationally identified all of the predicted targets of our set of tumor suppressor miRNAs ATAD2B  SPIN4  MBTD1  MYB  PTBP2  ATL2  TNF  HBP1  NXT2  YWHAE  RC3H2  GOLGA7  PIK3C2  HIVEP2  TMEM161B  CCNJ  CREG1  DNAJC10  HDAC8 ( Fig. 4B) . We then quantified the interaction of all targets with these miRNAs by adding their mirSVR scores, which is a computational prediction of miRNA-mRNA binding (21) , and then we did the same for the 30 most highly abundant miRNAs in T-ALL. The difference in mirSVR score is expressed on the x axis and identifies preferential binding by tumor suppressor miRNAs (toward the right) or by abundant miRNAs (to the left) (Fig. 4B) . Next, we excluded genes whose mRNA abundance was not increased in T-ALL samples compared to that in normal T cells (expressed on the y axis) on the basis of published gene expression data (22) . This approach left genes represented in quadrant I as the likely relevant targets of the tumor suppressor miRNAs (Fig. 4B and table S4 ).
Next, we applied a discriminative machine learning approach that used sparse logistic regression to prioritize genes in quadrant I. The machine learning algorithm learned to discriminate between tumor-suppressive miRNAs and random sets of 30 expressed miRNAs on the basis of their mirSVR-predicted target genes (21) . The use of a lasso constraint resulted in only a few target genes being included in the model with nonzero regression coefficients. To account for the small number of positive training examples, we performed a stability analysis by repeating the learning procedure 100 times with different random miRNA sets ( Fig. 4C and table  S5 ). We also applied this same model to another publically available gene expression data set (23) and to our RNAseq-based gene expression analysis of eight T-ALL and four normal T cell samples. The Myb oncogene emerged from this analysis as among the top candidate genes and was the only gene identified by all three analyses (Fig. 4D) . In detail, the machine learning approach identified Myb in 38% of iterative calculations in our RNAseq-based data set, in 27% in the expression data from Van Vlierberghe et al. (22) , and in 45% in the expression data from Homminga et al. (23) (fig. S4) . Hence, our computational strategy to discriminate unique from common miRNA targets identified Myb as a key effector of miRNA-mediated tumor suppression in T-ALL.
Characterization of Myb as a biologically relevant target of tumor suppressor miRNAs
The 3′UTR of Myb has three miR-150-binding sites (24) , as well as two binding sites each for miR-155 and miR-200c ( fig. S5A ). Accordingly, murine T-ALLs expressing miRZips or sponges specific for miR-150, miR-155, or miR-200 exhibited increased amounts of Myb mRNA and protein compared to control tumors ( fig. S5, B to D) . Furthermore, luciferase reporter assays performed with constructs expressing the 3′UTR of wild-type Myb or binding site mutant forms of the Myb 3′UTR showed direct and site-specific repression by miR-150, miR-155, and miR-200 ( fig. S5 , E to G). In vivo, overexpression of Myb in HPCs substantially accelerated the rate of development of ICN-dependent T-ALL in transplanted mice (median survival of 42.5 days) compared to mice that received HPCs transduced with empty vector (median survival of 77 days) (Fig. 4E) . Conversely, knockdown of Myb expression ( fig. S5H ) or overexpression of miR-150, miR-155, or miR-200 in established murine leukemic cells completely abrogated their leukemia-initiating capacity upon transplantation into syngeneic animals (25,000 cells via tail vein injection). Finally, expression of a cDNA encoding a mutant Myb deficient in all miRNA-binding sites prevented the antiproliferative effects of miR-150, miR-155, and miR-200 on human T-ALL cells (Fig. 4G and fig. S5I ). Finally, sponge-mediated inhibition of miRNA155 and, to a lesser extent, miR-200 caused an increase in Myb abundance ( fig. S5J ).
Characterization of HBP1 as an oncogenic target of tumor suppressor miRNAs in T-ALL
Inhibition of miR-29 and miR-31 promoted leukemogenesis in vivo (Fig. 3C  and fig. S3D ). With the same machine learning strategy, we found that in two of the three data sets, the gene encoding high mobility group boxtranscription factor (HBP1) was a target of both miR-29 and miR-31 (together with miR-155 and miR-200) (Fig. 4, C and D) . The binding sites for these tumor-suppressive miRNAs are conserved in the 3′UTR of murine Hbp1 (fig. S6A ), and consequently, mouse tumors arising as a result of sponge-mediated repression of these miRNAs showed a statistically significant increase in Hbp1 expression ( fig. S6B) . We examined the potential oncogenic effect of Hbp1 expression and found a statistically significant increase in the rate of disease development in an ICN-dependent T-ALL model (median survival: 40 days) ( fig. S6, C and D) . HBP1 has been implicated in the suppression of the cell cycle regulator p21 (25) as well as in the induction of CD2 expression in T cells (26, 27) . Hence, our analysis of the target genes of tumor suppressor miRNAs has uncovered a previously uncharacterized leukemogenic function for HBP1.
Coordinate control of tumor suppressor miRNAs by c-Myc in T-ALL
Chang et al. (28) reported the control of miRNA expression by MYC, and they identified several miRNAs whose expression was repressed by MYC, including miR-29 and miR-150. Myc is a direct effector of NOTCH1 (29, 30) . We took advantage of a tamoxifen-inducible dominant-negative MYC protein (omomyc ER ) to test whether MYC was required for the expression of tumor suppressor miRNAs in T-ALL (31, 32) . Briefly, omomyc forms transcriptionally inactive heterodimers with all endogenous MYC proteins (c-MYC, N-MYC, and L-MYC) by blocking the interaction of MYC with its binding partner MAX (32) . We introduced omomyc ER into KoptK1 T-ALL cells and, after tamoxifen treatment, measured the abundances of miRNAs of interest by qRT-PCR analysis. We found that the abundances of miR-31, miR-150, and miR-155 were statistically significantly reduced in cells with omomyc ER compared to those in control cells ( fig. S6E ). MYC is under the transcriptional control of NOTCH1, and accordingly, treating KoptK1 cells with Compound E, a g-secretase inhibitor (which prevents cleavage of NOTCH1 and generation of the ICN), led to a statistically significant increase in the abundances of miR-150 and miR-155, as well as a trend toward increased amounts of miR-31 ( fig. S6F) . Hence, repression of the expression of a subset of tumor suppressor miRNAs in T-ALL cells was a consequence of NOTCH and MYC activation.
DISCUSSION
Our study provides insights into the pathogenesis of T cell leukemia. We report a large-scale analysis of miRNA expression profiles, and we identified and functionally validated five tumor suppressor miRNAs and their biological targets in T-ALL. Among a larger set of differentially expressed miRNAs, only miR-29, miR-31, miR-150, miR-155, and miR-200 behaved as tumor suppressors whose inactivation promoted leukemogenesis. The activities of these miRNAs are tissue-specific, and miR-29 and miR-155 have tumor-promoting activities in B lymphocytes and myeloid cells (33) (34) (35) (36) (37) . This tissue specificity is consistent with the notion that lineage-specific gene expression programs determine the target repertoire, and therefore the biological consequences, of miRNA inactivation. Conversely, we found that miRNAs also controlled the abundance of lineage-restricted transcription factors, such as Myb. Specifically, the convergence of three tumor suppressor miRNAs that were lost (or decreased in abundance) across the T-ALL samples that we analyzed reveals a widespread mechanism of Myb activation and suggests an alternative oncogenic mechanism to that of rare chromosomal gains affecting the Myb locus (38) (39) (40) . An oncogenic function of Myb has been described in certain leukemias, including acute myeloid leukemia (41) and T-ALL (38) . In T-ALL, Myb overexpression blocks the differentiation of immature T cells, whereas its knockdown reverses this effect (38) . Multiple mechanisms lead to Myb overexpression in T-ALL, including mutation or miR-223-mediated repression of the E3 ubiquitin ligase Fbxw7 (7, (42) (43) (44) , increased transcription (45) , and increased eIF4A (eukaryotic initiation factor 4A)-dependent translation of Myb mRNA (46) . These events are not mutually exclusive, which is suggestive of additive effects in T-ALL pathogenesis. MYB has been an elusive drug target; however, histone deacetylase inhibitors such as SAHA (suberoylanilide hydroxamic acid ) (47) , which can impede Myb expression, and the natural compound Silvestrol, which potently blocks the translation of Myb mRNA (46) , might be effective in the treatment of T-ALL.
Our study revealed a Myc-dependent network of tumor suppressor miRNAs in T-ALL. Studies of Dicer-deficient mice have suggested a widespread role for miRNAs in cancer (48, 49) ; however, only a small number of miRNAs are targets of genomic deletions or behave as tumor suppressors in loss-of-function studies (13) (14) (15) . Conceivably, the overlapping and pleiotropic on-target effects of miRNAs have evolved to minimize the effects of losing individual miRNAs. This notion is borne out in systematic knockout studies in which the loss of miRNAs is most associated with minimal or absent phenotypes (10, 11) . Our results identify a small number of functionally validated tumor suppressor miRNAs. The expression of these miRNAs is repressed upon MYC activation, and this links their expression directly to a key oncogenic driver in T-ALL. Notably, these miRNAs show substantial convergence on Myb and HBP1, and their loss largely alleviates miRNA-mediated control of the expression of these genes. To identify such distinct miRNA targets, we developed a discriminatory machine learning tool. This method is specifically useful in deciphering the effects of miRNA inactivation and takes advantage of the overlapping target gene repression to identify a small number of unique targets whose expression is expected to change upon miRNA inactivation. In summary, we report a functionally interconnected set of tumor suppressor miRNAs that converge on key T-ALL-associated oncogenes.
MATERIALS AND METHODS
T-ALL patient samples and cell lines
Diagnostic bone marrow samples of 50 T-ALL patients were obtained from different European centers (UZ Ghent, Ghent; UZ Leuven, Leuven; Hôpital Purpan, Toulouse; CHU de Nancy-Brabois, Vandoeuvre-LesNancy). The resulting T-ALL patient cohort consisted of 15 TAL/LMO (7 LMO2 and 8 SIL-TAL), 12 HOXA [4 MLL, 6 inv(7)(p15q35), and 2 CALM-AF10], 10 TLX3, 5 TLX1, and 8 cases that could not be categorized. Total RNA was isolated from the bone marrow samples with the miRNAeasy Mini Kit (Qiagen). This study (2008/531) was approved by the Medical Ethical Commission of Ghent University Hospital (Belgium, registration B67020084745). Eighteen T-ALL cell lines were cultured in RPMI 1640 (Invitrogen), 15% fetal calf serum, 1% penicillin, 1% streptomycin, 1% kanamycin, and 1% glutamine. 
CD4
+ CD8 + CD3 + , CD3 + CD4 + CD8 − , and CD3 + CD4 − CD8 + ) were obtained by FACS and MACS (magnetic cell sorting). CD34 + cells were isolated with CD34 microbeads (Miltenyi Biotec) (50) . Double-positive thymocytes were isolated by staining with fluorescein isothiocyanate (FITC)-conjugated anti-CD3, phycoerythrin (PE)-conjugated anti-CD8, and allophycocyanin (APC)-conjugated anti-CD4 antibodies. Single-positive thymocytes were depleted of CD1 + thymocytes by Dynabeads (Dynal Biotech) and subsequently labeled with anti-CD3-FITC, anti-CD8-PE, and anti-CD4-APC. The purity of the different subsets of normal T cell populations was always at least 98%. Profiling of miRNAs was performed with stem-loop reverse transcription primers for the synthesis of cDNA from miRNA, followed by a preamplification step and real-time PCR analysis (Applied Biosystems) as described previously (51) . Briefly, 20 ng of total RNA was reverse-transcribed with the Megaplex reverse transcription stem-loop primer pool for the cDNA synthesis of 448 small RNAs, including 430 miRNAs and 18 small RNA controls. Preamplification of cDNA was performed in a 14-cycle PCR with TaqMan PreAmp Master Mix (2×) and the PreAmp Primer Mix (5×) (Applied Biosystems) consisting of a miRNA-specific forward primer and a universal reverse primer (52) . Finally, the 448 small RNAs were profiled for each sample with a 40-cycle PCR protocol. SDS software version 2.1 was used to calculate the raw quantification cycle (Cq) values with automatic baseline settings and a threshold of 0.05. For normalization of the qRT-PCR data of the miRNA expression profiles, we used the mean expression value of all expressed miRNAs in a given sample as the normalization factor; miRNAs with a Cq value >32 were considered to be below the limit of detection (16) .
Cell culture and treatment, viability and proliferation assays, and plasmid constructs T-ALL cell lines and tumors were virally transduced as described previously (53, 54) . miRNA-cDNA expression constructs and miRNA sponges were cloned in murine stem cell virus (MSCV)-based retroviral vectors (4, 17) , whereas miR-ZIP antagomirs were expressed from lentiviral vectors (System Biosciences), including MZIP29a-PA-1, MZIP150-PA-1, MZIP155-PA-1, MZIP200c-PA-1, and the scrambled control MZIP000-PA-1. miRNA-specific sponges were designed and tested as described previously (19) .
In vitro screens of individual miRNAs or sponges
The T-ALL cell lines KoptK1, RPMI-8402, DND41, and TALL-1 were transduced with HIV-based lentiviral vectors that express both the miRNA (as indicated) and GFP. Seventy-two hours after infection, the percentage of GFP + cells was determined by flow cytometric analysis. Cells were then monitored every 48 hours for the expression of GFP over a 14-day period. Similarly, MOHITO cells were transduced with retroviruses expressing miRNA-specific sponges and GFP and were then monitored for GFP enrichment or depletion at the population level by flow cytometry.
Generation of murine T-ALL and transplantation assays
The mouse T-ALL model has been described previously (17, 55) . Briefly, fetal liver stem cells (from 13.5-to 14.5-day-old embryos) derived from either wild-type or miRNA knockout mice were virally transduced with retrovirus expressing ICN together with the indicated miRNA inhibitor or gene (cDNA encoding Myb or Hbp1) and then were transplanted into lethally radiated syngeneic C57BL/6 host mice. Survival data were analyzed in Kaplan-Meier format with the log-rank (Mantel-Cox) test for statistical significance. Analysis of cell surface markers was performed as described previously (55) . For transplantation assays, primary murine leukemic cells derived from ICN and a dominant-negative form of IKAROS, IK6-expressing HPCs were transduced with MSCV-based vectors expressing miR-150, miR-155, miR-200c, a short-hairpin against Myb (shMyb-2), or empty vector control. Cells were then selected in culture medium containing puromycin and were injected into sublethally radiated syngeneic recipient mice (25,000 cells per mouse).
Western blotting and qRT-PCR analysis
Western blotting analysis was performed with whole-cell lysates as described previously (42) . Antibodies used were specific for c-Myb (clone C-19, 1:500; Santa Cruz Biotechnology, sc-517), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cell Signaling), and actin (1:5000; Sigma, AC-15). Total RNA was extracted from cells with the AllPrep kit (Qiagen). Synthesis of cDNA, qRT-PCR assays, and data analysis by the DDC t method were performed as described previously (40) . The following TaqMan Gene Expression Assays were used: c-Myb (Hs00920554_m1, Applied Biosystems) and Hbp1 (Mm00462715_m1, Applied Biosystems). The abundances of these mRNAs were normalized to those of housekeeping genes, including human b-actin or GusB and mouse actin or GAPDH (Applied Biosystems). To measure miRNA abundance, the following TaqMan assays were used: miR-29a (TM: 002112), miR-31 (TM: 002279), miR-150 (TM: 473), miR-155 (TM: 479), and miR200c (TM: 002300). The abundances of these miRNAs were normalized to that of U6 small nuclear RNA (TM: 001093, Applied Biosystems).
Discriminative model with sparse logistic regression
To determine the shared targets of tumor suppressor miRNAs that were not also targeted by highly abundant miRNAs in T-ALL, we used logistic regression with a lasso constraint to discriminate between tumor suppressor miRNAs (+1 class) and highly abundant miRNAs (-1 class) on the basis of feature vectors of predicted target genes. We used prediction scores from miRSVR (http://miRNA.org) as features and restricted to a subset of genes that were statistically significantly increased in abundance in human T-ALL samples on the basis of two published data sets (22, 23) and our RNA sequencing analysis of eight T-ALL samples. The logistic regression model expresses the conditional probability of belonging to the tumor suppressor miRNA class as:
where x miR,g is the mirSVR score of the miRNA for a given gene "g," and w g is the regression coefficient for the gene g. For sparse logistic regression, the optimization problem consists of minimizing the negative log likelihood plus a lasso term:
We implemented sparse logistic regression with the glmnet R software package. Because we had a small set of six tumor suppressor miRNAs on which to train, we fixed our positive training examples and repeatedly subsampled nine highly abundant miRNAs to train slightly different regression models. After training a total of 100 different models, target genes were ranked according to how frequently they were included with positive regression coefficients in these models.
Target prediction
With the seed sequence (position 2:8) for each miRNA, we identified conserved mRNA targets by requiring the complementary sequence to occur in the 3′UTRs of both mouse and human orthologous mRNAs. We used the minimum number of seed matches from both UTRs as the conserved 7-mer count for each miRNA:mRNA pair. We used Biopython to extract 3′UTR sequences for mouse and human with RefSeq (Release 42). The longest 3′UTR was used when multiple RefSeq transcripts were present for a single gene.
Enrichment of miRNAs
The empirical P value for the enrichment of miRNAs in Table 1 was determined by selecting 10,000 random samples of genes (of size equal to the set of tumor suppressor genes) from the full list of human genes for which we had 3′UTRs and target predictions. We computed the sum of TargetScan context scores for each broadly conserved miRNA seed family relative to each of these random gene sets and ranked the miRNA families according to these scores. This procedure generated a randomized version of Table 1 for each randomly selected gene set. We then calculated enrichment scores for these rankings with a Wilcoxon rank sum statistic comparing the "positive" miRNAs (those that passed all screens) to all other miRNAs. Finally, to compute the empirical P value, we counted the number of times over the 10,000 randomly sampled gene sets that we obtained a Wilcoxon rank sum score as good as or better than the one we obtained with the tumor suppressor gene set. We found that 428 random samplings performed as well as or better than the tumor suppressor gene set, which corresponded to a statistically significant empirical P value (P < 0.043).
Comparison of cytogenetic and mutational subgroups
Differential miRNA expression analysis was performed with t tests for groups of patient samples by cytogenetic criteria or by the presence and absence of Notch1 or Fbxw7 mutations (7). Cell lines were grouped by the indicated mutations and sensitivity to g-secretase inhibitors, as reported previously (43) . Benjamini-Hochberg correction was used for multiple hypotheses correction.
Luciferase assays
The 3′UTR of human Myb was a gift from J. Lieberman (Harvard Medical School). For the Myb 3′UTR luciferase assays, wild type refers to the complete 1191-base pair (bp) 3′UTR fragment that contains all of the miRNA-binding sites. For miR-150, miR-155, and miR-200c, site 1, site 2, and site 3 refer to mutation of the predicted miRNA-binding sites located in the positions indicated from left to right in fig. S5A . For miR-150, the positions of each site correspond to site 1 (base pairs 87 to 93), site 2 (base pairs 829 to 836), and site 3 (base pairs 904 to 911). For miR-155, the positions of each site correspond to site 1 (base pairs 15 to 21) and site 2 (base pairs 431 to 437). For miR-200c, the positions of each site correspond to site 1 (base pairs 319 to 325) and site 2 (base pairs 373 to 379). Site 1,2 or Site 1,2,3 refers to two or more mutated sites. The luciferase assays were performed as described previously (56) . The primers used for mutagenesis of regions of the 3′UTR are listed in table S6.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/7/352/ra111/DC1 Fig. S1 . Changes in the abundances of miRNAs in T-ALL. Fig. S2 . Competition experiments testing the antileukemic potential of various miRNAs. Fig. S3 . Additional data concerning the in vivo tumor suppressor activity of various miRNAs. Fig. S4 . Validation data sets confirm Myb as a relevant target of tumor suppressor miRNAs. Fig. S5 . Myb is a target of three tumor suppressor miRNAs in T-ALL. Table 1 . Groups of miRNAs used in the lasso regression analysis. The positive set includes tumor suppressor miRNAs, whereas the negative set includes highly abundant miRNAs.
Positive set
Negative set miR-29a/c, miR-31, miR-150, miR-155, miR-200 miR-223, miR-222, miR-30c, miR-30a, miR-342-3p, miR-19b, miR-191, miR-181a, miR-376a, miR-92a, miR-20a, miR-19a, miR-106b, miR-17, miR-196a, miR-142-3p, miR-15b, miR-486-5p, miR-21, miR-662, miR-26a, miR-26b, miR-451, miR-30b, miR-617, miR-16, miR-140-5p, miR-181d, miR-93 Fig. S6 . HBP1 accelerates the rate of development of ICN-driven leukemia. Table S1 . Expression profiles of miRNAs in normal T cells, T-ALL patient samples, and T-ALL cell lines. Table S2 . miRNAs with decreased abundance in T-ALL samples as compared to normal T cell subsets based on subtype. Table S3 . Expression profiles of miRNAs for previously reported candidate tumor suppressor miRNAs. Table S4 . Identification of target genes. Table S5 . Full list of genes from the lasso regression model. Table S6 . Sequences of primers used for making mutations in the Myb 3′UTR.
